Real world experience with an indigenously manufactured stent Cobal C--a retrospective study

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomaterials Engineering

Background:

• Second-generation cobalt-chromium bare metal stents offer advantages over first-generation stainless steel stents.
• Thin stent struts are associated with reduced clinical and angiographic adverse outcomes.

Purpose of the Study:

• To evaluate the long-term clinical and angiographic outcomes of the indigenously manufactured Cobal+C™ (Relisys) cobalt-chromium bare metal stent.
• Assess the safety and efficacy of this specific thin-strut stent design in coronary angioplasty patients.

Main Methods:

• Retrospective study of 268 patients undergoing coronary angioplasty with Cobal+C stents.
• Clinical follow-up at a minimum of nine months via telephone; angiographic follow-up in 80 randomly selected patients between 9-15 months.
• Primary endpoints included major adverse cardiac events (MACE) at nine months and binary restenosis rate.

Main Results:

• The study population included 34% diabetics and 33% with acute myocardial infarction; 17% were female.
• Major adverse cardiac events (MACE) at nine months were 4.5%, with a target lesion revascularization (TLR) of 0.3%.
• The binary restenosis rate was 21%, with higher rates observed in patients with longer stent lengths and medication non-compliance.

Conclusions:

• Relisys Cobal+C stents demonstrated favorable long-term clinical and angiographic outcomes.
• The low incidence of MACE and acceptable binary restenosis rates support the use of these bare metal stents.